AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26888217
Drug: Everolimus (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (starting dose 1.5 mg/day; C0 3‐8 ng/mL) with cyclosporine
Trial: 26888217
Drug: Everolimus (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (starting dose 3 mg/day; C0 3‐8 ng/mL) with tacrolimus
Trial: 26888217
Drug: Mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mycophenolic acid (1.44 g/day or 2 g/day) with tacrolimus
Trial: 21142632
Drug: Erythropoietin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin therapy (50 IU/kg/week) for 2 weeks
Trial: 17705013
Drug: Pelvic SPECT
RxNorm normalized name: spelt seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic SPECT preceded by IV injection of 0.5 mg/kg furosemide and IV infusion of 500 cc saline (Group II)
Trial: 15728297
Drug: L-arginine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine administered intravenously at the acute phase or orally at the interictal phase
Trial: 15728297
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of L-arginine within 30 minutes of a stroke
Trial: 11927706
Drug: Carnitine supplementation
RxNorm normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carnitine supplementation (30 mg/kg/d)
Trial: 7610591
Drug: Topical non-selective
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical non-selective and selective beta-adrenoceptor antagonists
Trial: 2116265
Drug: Intravenous nutrition
RxNorm normalized name: Intravenous nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nutrition (IVN) support
Trial: 2116265
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no intravenous nutrition)
Trial: 216027
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg MSH/ACTH4-10
Trial: 216027
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg MSH/ACTH4-10
Trial: 24072634
Drug: Micronized progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized progesterone combined with transdermal oestradiol
Trial: 24072634
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate combined with transdermal oestradiol
Trial: 18931824
Drug: TG4010 10(8)
RxNorm normalized name: TG4010
DrugBank: TG4010 (DB06584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG4010 10(8) pfu weekly for 6 weeks, then every 3 weeks
Trial: 16393600
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream once daily for 1 month after curettage and electrodesiccation (C&D)
Trial: 16393600
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream once daily for 1 month after curettage and electrodesiccation (C&D)
Trial: 11060828
Drug: Colesevelam hydrochloride
RxNorm normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam hydrochloride with statins (lovastatin, simvastatin, atorvastatin)
Trial: 8828781
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of rHuEPO into the venous drip chamber using the Fresenius delivery system
Trial: 8828781
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of rHuEPO into the venous port
Trial: 8828781
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of rHuEPO into the venous drip chamber
Trial: 1444083
Drug: Topical atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical atropine immediately after trabeculectomy
Trial: 1444083
Drug: Topical atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical atropine beginning treatment on the first postoperative day
Trial: 3894258
Drug: tiaprofenic acid
RxNorm normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiaprofenic acid (600 mg daily)
Trial: 3894258
Drug: ibuprofen (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen (1.2 g daily)
Trial: 28650195
Drug: Mindfulness-based addiction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based addiction treatment (MBAT)
Trial: 15284073
Drug: L‐NMMA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐NMMA (3 mg/kg during the initial 5 min and subsequent continuous infusion of 50 mug.kg(‐1).min(‐1) in saline)
Trial: 9072590
Drug: Finasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5 alpha-reductase inhibitor)
Trial: 29446445
Drug: Lenograstim 5
RxNorm normalized name: LENOGRASTIM
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenograstim 5 µg/kg
Trial: 29446445
Drug: Biosimilar filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Biosimilar filgrastim 10 µg/kg
Trial: 14635971
Drug: Standard asthma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard asthma care with information on the stepwise treatment approach, a written action plan, and inhaler technique training
Trial: 9429041
Drug: Intravenous PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PCA fentanyl
Trial: 8397997
Drug: Enalaprilat (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalaprilat (2.5 mg intravenously)
Trial: 3301709
Drug: l(‐)ephedrine hydrochloride
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: l(‐)ephedrine hydrochloride (50 mg three times a day per os)
Trial: 27289457
Drug: PENS of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PENS of dermatome T6 with a self-applied patch associated with diet (group 2)
Trial: 25071023
Drug: Exenatide (GLP-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (GLP-1 receptor agonist)
Trial: 25071023
Drug: Exendin 9-39
RxNorm normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exendin 9-39 (GLP-1 receptor blockade)
Trial: 16402745
Drug: Sequential recall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential recall or serial position identification task
Trial: 12732401
Drug: Fenofibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (200 mg/daily)
Trial: 12732401
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (200 mg/daily)
Trial: 12732401
Drug: Fenofibrate plus
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate plus Coenzyme Q10 (200+200 mg daily)
Trial: 9798024
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (500 mg twice a day for 14 days)
Trial: 2349932
Drug: Aspartame (APM)
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (APM) sweetened soda (1150 g per day for 3 weeks)
Trial: 2349932
Drug: High-fructose corn
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fructose corn syrup (HFCS) sweetened soda (1150 g per day for 3 weeks)
Trial: 30587225
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg doxycycline
Trial: 30587225
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg doxycycline
Trial: 30587225
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg minocycline
Trial: 30587225
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg minocycline
Trial: 30587225
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg doxycycline and minocycline
Trial: 30587225
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg doxycycline and minocycline
Trial: 27525966
Drug: Vortioxetine (fixed-dose)
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vortioxetine (fixed-dose)
Trial: 24326004
Drug: Glargine insulin
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glargine insulin delivery by pen device
Trial: 24326004
Drug: Glargine insulin
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glargine insulin delivery by vial/syringe
Trial: 24326004
Drug: Patient preference
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient preference for insulin delivery method
Trial: 23676198
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (subanesthetic dose)
Trial: 18477227
Drug: 2.5 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg/day cyclosporin (CsA) treatment
Trial: 16034820
Drug: Nutrition (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition (intravenous glucose with amino acids)
Trial: 16034820
Drug: Glucose only
RxNorm normalized name: Glucose only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose only (intravenous glucose without amino acids)
Trial: 12167548
Drug: Standard inpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard inpatient withdrawal treatment using clonidine plus symptomatic medication
Trial: 2209499
Drug: 1.5 l
RxNorm normalized name: NUTREN 1.5 LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 l Golytely preparation
Trial: 2209499
Drug: 3 l
RxNorm normalized name: D3 Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 l Golytely preparation
Trial: 2209499
Drug: 1.5 l
RxNorm normalized name: NUTREN 1.5 LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 l Golytely preparation (post-study routine)
Trial: 7232842
Drug: Radiotherapy, chemotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy, chemotherapy, and MER
Trial: 31661974
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (N-acetylcysteine and mitochondrial agents)
Trial: 31109838
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both
Trial: 9676035
Drug: Control subjects
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control subjects (no G-CSF treatment)
Trial: 23788069
Drug: Uncertainty about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncertainty about receiving medicine when pushing the PCA button
Trial: 21255195
Drug: Mianserin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (20 mg; p.o.)
Trial: 12713062
Drug: SQV-SGC 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQV-SGC 1200 mg three times daily plus two NRTIs
Trial: 12713062
Drug: SQV-SGC 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQV-SGC 1600 mg twice daily plus two NRTIs
Trial: 12713062
Drug: SQV-SGC 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQV-SGC 1200 mg twice daily plus NFV 1250 mg twice daily plus one NRTI
Trial: 10738041
Drug: Large-volume leukapheresis
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large-volume leukapheresis (LVL) with heparin
Trial: 8805090
Drug: d,l‐fenfluramine hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d,l‐fenfluramine hydrochloride (60 mg orally)
Trial: 1637895
Drug: Prophylaxis therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylaxis therapy for pneumocystis carinii pneumonia
Trial: 1637895
Drug: High-dose 3-azido-3-deoxythymidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose 3-azido-3-deoxythymidine (AZT)
Trial: 1637895
Drug: Low-dose 3-azido-3-deoxythymidine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose 3-azido-3-deoxythymidine (AZT)
Trial: 6706305
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) at 2.1 mg X kg‐1 X day‐1
Trial: 6706305
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) at 4.2 mg X kg‐1 X day‐1
Trial: 6706305
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) at 8.4 mg X kg‐1 X day‐1
Trial: 6706305
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) at 16.2 mg X kg‐1 X day‐1
Trial: 6706305
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid (CDCA) at 16.9 mg X kg‐1 X day‐1
Trial: 30266030
Drug: iCBT (internet-delivered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iCBT (internet-delivered cognitive behavioral therapy)
Trial: 22709747
Drug: Standard optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard optimal medical therapy
Trial: 20006197
Drug: ED-administered antibiotics
RxNorm normalized name: Ed-APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ED-administered antibiotics
Trial: 17559725
Drug: Infliximab therapy
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab therapy for 6 weeks
Trial: 15770833
Drug: Cefepime 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 150 mg/kg/day
Trial: 15770833
Drug: Ceftazidime 150
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime 150 mg/kg/day + Amikacin 15 mg/kg/day
Trial: 12390444
Drug: Cetirizine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (0.25 mg/kg)
Trial: 7405925
Drug: Post-antibiotic therapy
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-antibiotic therapy
Trial: 31840969
Drug: Ocular cleansing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular cleansing with sterile gauze (group A) 3 times daily for 48 hours
Trial: 31840969
Drug: Ocular cleansing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocular cleansing with Iridium® baby gauze containing Echinacea angustifolia (group B) 3 times daily for 48 hours
Trial: 23024190
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5 mg infusion)
Trial: 15221295
Drug: Gated SPECT
RxNorm normalized name: spelt seed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gated SPECT with 99mTc‐sestamibi injection
Trial: 12235452
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of enoxaparin (1.5 mg/kg once daily for 4 days)
Trial: 12235452
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of enoxaparin (1.5 mg/kg)
Trial: 9602765
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose radiotherapy of 5 Gy at the operation field preoperatively
Trial: 7747098
Drug: Enhanced potency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced potency inactivated poliovirus vaccine (EIPV)
Trial: 20961474
Drug: Wellness Workshop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wellness Workshop (WW) CD‐ROM + Treatment as Usual (TAU)
Trial: 14745389
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution sprayed on the major duodenal papilla (placebo)
Trial: 9014067
Drug: Heparin-dihydroergotamine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-dihydroergotamine 0.5 mg + 5,000 IU twice a day
Trial: 1396108
Drug: Buprenorphine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.4 mg or 0.8 mg/70 kg)
Trial: 1396108
Drug: Buprenorphine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.4 mg or 0.8 mg/70 kg) + Naloxone (0.4 mg or 0.8 mg/70 kg)
Trial: 3888241
Drug: Lorazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (1 or 2.5 mg)
Trial: 28214653
Drug: NACT followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NACT followed by CCRT (cisplatin 80 mg/m2 d1 and fluorouracil 800 mg/m2 civ d1‐5 for two cycles before CCRT)
Trial: 28214653
Drug: CCRT alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCRT alone (cisplatin 80 mg/m2 every 3 weeks concurrently with radiotherapy)
Trial: 25277597
Drug: Cyclosporine treatment
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine treatment for 2 years
Trial: 21684425
Drug: Pandemic live
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pandemic live attenuated influenza vaccine (PLAIV) against the influenza A (H1N1) virus
Trial: 21684425
Drug: H5N2 pandemic
RxNorm normalized name: pangamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H5N2 pandemic live attenuated influenza vaccine (PLAIV)
Trial: 21684425
Drug: Seasonal live
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seasonal live attenuated influenza vaccine (LAIV)
Trial: 18307373
Drug: Duloxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (10 mg IV infusion over 30 minutes or 60 mg orally) with fluvoxamine (100 mg orally once daily)
Trial: 18307373
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg orally twice daily)
Trial: 18307373
Drug: Fluvoxamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (100 mg orally once daily)
Trial: 18307373
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg orally)
Trial: 17000242
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin therapy
Trial: 17000242
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin therapy (enoxaparin sodium)
Trial: 10509768
Drug: Breakfast cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breakfast cereal (80 g for men, 60 g for women) consumed at breakfast for six weeks
Trial: 8948303
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CyA) and parenteral gold therapy (PGT)
Trial: 8948303
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and parenteral gold therapy (PGT)
Trial: 28452665
Drug: Home-delivered cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-delivered cognitive-behavioral therapy (CBT) for depression
Trial: 21791142
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA (1.7 g daily for 3 months)
Trial: 15886433
Drug: Medical record
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical record (MR) - data collected hourly
Trial: 9800145
Drug: Oral methylnaltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylnaltrexone 19.2 mg/kg
Trial: 9800145
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 0.05 mg/kg
Trial: 6193350
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg MDL‐899
Trial: 6193350
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg MDL‐899 with 100 mg atenolol
Trial: 23688137
Drug: Sensorimotor enrichment
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensorimotor enrichment group (daily olfactory/tactile stimulation and paired sensory exercises)